Top Markets
Coin of the day
Carmell Therapeutics Corporation Carmell Therapeutics Corporation

Carmell Therapeutics Corporation

CTCX
Clasificación en acciones #36666
Carmell Therapeutics Corporation (CTCX) specializes in the creation of... Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.
Precio por acción
$0.117
Última sincronización: 2025-04-04
Capitalización bursátil
$2.45M
Cambio (1 día)
-13.59%
Cambio (1 año)
0.00%
País
US
Comercio Carmell Therapeutics Corporation (CTCX)

Categoría

Ratio P/B de Carmell Therapeutics Corporation (CTCX)
Ratio P/B al August 2026 TTM: -0.06
Según los informes financieros más recientes y el precio de las acciones de Carmell Therapeutics Corporation, el ratio P/B actual (TTM) es -0.06. Al final de 2023, el ratio P/B era 95.93.
Historial del ratio P/B de Carmell Therapeutics Corporation desde 2021 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
2026 (TTM) -0.06 -99.85%
2024 -37.13 -138.70%
2023 95.93 -161.62%
2022 -155.68 -19.29%
2021 -192.90 0.00%
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.3419 -11,404.63%
US
6.2413 -11,225.31%
NL
- -
CH
- -
KR
3.4612 -6,269.70%
BE